Female patients with urothelial carcinoma may derive less benefit for the antibody-drug conjugate (ADC) enfortumab vedotin (EV) than their male counterparts, according to a poster presented at the European Society for Medical Oncology (ESMO)…
Do Men and Women With Urothelial Cancer Have Different Responses to Enfortumab Vedotin?
